Loading clinical trials...
Loading clinical trials...
A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers
Conditions
Interventions
SF2a-TT15 vaccine
SF2a-TT15 vaccine + adjuvant
+2 more
Locations
1
Israel
Tel Aviv Souraski Medical Center
Tel Aviv, Israel
Start Date
September 1, 2016
Primary Completion Date
June 1, 2017
Completion Date
December 1, 2017
Last Updated
April 11, 2018
NCT05959616
NCT05182749
NCT05156528
Lead Sponsor
Institut Pasteur
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions